In the present study, we investigated the role of SEMA3A in renal injury by using a Doxorubicin (Dox)-induced podocytopathy mouse model, an experimental model of focal segmental glomerulosclerosis with time-dependent podocyte apoptosis [13], and examined the therapeutic effect of a selective SEMA3A inhibitor (SM-345431: vinaxanthone, SEMA3A-I) [14,15,16]. The gene discussed is SEMA3A; the disease is focal segmental glomerulosclerosis.